DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Reslizumab is an investigational drug.
There have been 18 clinical trials for Reslizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Asthma, Pulmonary Eosinophilia, and Inflammation. The leading clinical trial sponsors are Teva Branded Pharmaceutical Products, R&D Inc., GlaxoSmithKline, and Teva Pharmaceuticals USA.
There are fourteen US patents protecting this investigational drug and two hundred and sixty international patents.
Recent Clinical Trials for Reslizumab
|Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab||Sociedad Española de Neumología y Cirugía Torácica||Phase 2|
|A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma||Teva Branded Pharmaceutical Products, R&D Inc.||Phase 3|
|An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation||Teva Branded Pharmaceutical Products, R&D Inc.||Phase 4|
Top disease conditions for Reslizumab
Top clinical trial sponsors for Reslizumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Reslizumab||See Pricing||Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders||Knopp Biosciences LLC (Pittsburgh, PA)||See Pricing|
|Reslizumab||See Pricing||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||See Pricing|
|Reslizumab||See Pricing||Compositions and methods for treating chronic urticaria||Knopp Biosciences LLC (Pittsburgh, PA)||See Pricing|
|Reslizumab||See Pricing||Soft lozenge compositions||Patheon Softgels, Inc. (High Point, NC)||See Pricing|
|Reslizumab||See Pricing||Cholestosome vesicles for incorporation of molecules into chylomicrons||THERASYN SENSORS, INC. (Eggertsville, NY)||See Pricing|
|Reslizumab||See Pricing||Stabilizing alkylglycoside compositions and methods thereof||Aegis Therapeutics LLC (San Diego, CA)||See Pricing|
|Reslizumab||See Pricing||Stabilizing alkylglycoside compositions and methods thereof||Aegis Therapeutics, LLC (San Diego, CA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|